Pramipexole, Amisulpride

Phase 1Small molecule

Pramipexole, Amisulpride is one of 3 small molecule programs targeting Compulsive behaviors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Compulsive BehaviorsActive, not recruiting

Compulsive BehaviorsPhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Compulsive Behaviors

#DrugCompanyPhaseTrials

Cymbalta

Alnylam Pharmaceuticals

Campral

1 3

Pramipexole, Amisulpride

GSK

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Compulsive behaviors1 trial

Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors

Completed· GSK logo

GSK·Phase 1·NCT00471588·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pramipexole, Amisulpride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pramipexole, Amisulpride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pramipexole, Amisulpride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GSK

Pramipexole, Amisulpride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Compulsive behaviors1 trial

References

Drug Info

Quick Facts

Related News